|
1
|
Barrett DM, Singh N, Porter DL, Grupp SA
and June CH: Chimeric antigen receptor therapy for cancer. Annu Rev
Med. 65:333–347. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lechler R and George AJT: 21.
Transplantation and rejection: Immunology. Roitt I, Bristoff J and
Male D: Immunology (5th). (Philadelphia, NJ). Mosby. 1998.
|
|
3
|
Boise LH, Minn AJ, Noel PJ, et al: CD28
costimulation can promote T cell survival by enhancing the
expression of Bcl-XL. Immunity. 3:87–98. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Riddell SR and Greenberg PD: The use of
anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand
human antigen-specific T cells. J Immunol Methods. 128:189–201.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Levine BL, Ueda Y, Craighead N, Huang ML
and June CH: CD28 ligands CD80 (B7-1) and CD86 (B7-2) induce
long-term autocrine growth of CD4+ T cells and induce
similar patterns of cytokine secretion in vitro. Int
Immunol. 7:891–904. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Levine BL, Cotte J, Small CC, et al:
Large-scale production of CD4+ T cells from HIV-1-infected donors
after CD3/CD28 costimulation. J Hematother. 7:437–448. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gendler S, Taylor-Papadimitriou J, Duhig
T, Rothbard J and Burchell J: A highly immunogenic region of a
human polymorphic epithelial mucin expressed by carcinomas is made
up of tandem repeats. J Biol Chem. 263:12820–12823. 1988.PubMed/NCBI
|
|
8
|
Hansen J, Martin P and Nowinski R:
Monoclonal antibodies identifying a novel T-Cell antigen and Ia
antigens of human lymphocytes. Immunogenetics. 10:247–260. 1980.
View Article : Google Scholar
|
|
9
|
Wright SE, Khaznadar R, Wang Z, Quinlin
IS, Rewers-Felkins KA, Phillips CA and Patel S: Generation of
MUC1-stimulated mononuclear cells using optimized conditions. Scand
J Immunol. 67:24–29. 2008.PubMed/NCBI
|
|
10
|
Wright SE, Rewers-Felkins KA, Quinlin IS,
Eldridge PW, Zorsky PE, Klug PP, Phillips CA and Philip R: Adoptive
immunotherapy of mucin1 expressing adenocarcinomas with mucin1
stimulated human peripheral blood mononuclear cells. Int J Mol Med.
9:401–404. 2002.PubMed/NCBI
|
|
11
|
Wright SE, Kilinski L, Talib S, Lowe KE,
Burnside JS, Wu JY, Dolby N, Dombrowski KE, Lebkowski JS and Philip
R: Cytotoxic T lymphocytes from humans with adenocarcinomas
stimulated by native MUC1 mucin and a mucin peptide mutated at a
glycosylation site. J Immunother. 23:2–10. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wright SE, Rewers-Felkins K A, Quinlin IS,
Fogler WE, Phillips CA, Townsend M, Robinson W and Philip R:
MHC-unrestricted lysis of MUC1-expressing cells by human peripheral
blood mononuclear cells. Immunol Invest. 37:215–225. 2008.
|
|
13
|
Alajez NM, Schmielau J, Alter MD, Cascio M
and Finn OJ: Therapeutic potential of a tumor-specific,
MHC-unrestricted T-cell receptor expressed on effector cells of the
innate and the adaptive immune system through bone marrow
transduction and immune reconstitution. Blood. 105:4583–4589. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kanof ME and Smith PD: Preparation of
human mononuclear cell populations and subpopulations. Current
Protocols in Immunology. Coligan JE: (New York, NY, USA). John
Wiley & Sons, Inc. 71994.
|
|
15
|
Zhai YF, Esselman WJ, Oakley CS, Chang CC
and Welsch CW: Growth of MCF-7 human breast carcinoma in severe
combined immunodeficient mice: Growth suppression by recombinant
interleukin-2 treatment and role of lymphokine-activated killer
cells. Cancer Immunol Immunother. 35:237–245. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wunderlich J: Chromium Release Cytoxicity
Assay. Current Protocols in Immunology. Coligan JE: (New York, NY,
USA). John Wiley & Sons, Inc. 31994.
|
|
17
|
Levine BL, Bernstein WB, Connors M,
Craighead N, Lindsten T, Thompson CB and June CH: Effects of CD28
costimulation on long-term proliferation of CD4+ T cells in the
absence of exogenous feeder cells. J Immunol. 159:5921–5930.
1997.PubMed/NCBI
|
|
18
|
Frigault MJ, Lee J, Basil MC, Carpenito C,
Motohashi S, Scholler J, Kawalekar OU, Guedan S, McGettigan SE,
Posey AD Jr, et al: Identification of chimeric antigen receptors
that mediate constitutive or inducible proliferation of T cells.
Cancer Immunol Res. 3:356–367. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Künkele A, Johnson AJ, Rolczynski LS,
Chang CA, Hoglund V, Kelly-Spratt KS and Jensen MC: Functional
Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL
Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent
AICD. Cancer Immunol Res. 3:368–379. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kalamasz D, Long SA, Taniguchi R, Buckner
JH, Berenson RJ and Bonyhadi M: Optimization of human T-cell
expansion ex vivo using magnetic beads conjugated with
anti-CD3 and Anti-CD28 antibodies. J Immunother. 27:405–418. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li Y and Kurlander RJ: Comparison of
anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for
expanding human T cells: Differing impact on CD8 T cell phenotype
and responsiveness to restimulation. J Transl Med. 8:1042010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Maus MV, Thomas AK, Leonard DGB, Allman D,
Addya K, Schlienger K, Riley JL and June CH: Ex vivo
expansion of polyclonal and antigen-specific cytotoxic T
lymphocytes by artificial APCs expressing ligands for the T-cell
receptor, CD28 and 4-1BB. Nat Biotechnol. 20:143–148. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Singh H, Figliola MJ, Dawson MJ, Olivares
S, Zhang L, Yang G, Maiti S, Manuri P, Senyukov V, Jena B, et al:
Manufacture of clinical-grade CD19-specific T cells stably
expressing chimeric antigen receptor using Sleeping Beauty system
and artificial antigen presenting cells. PLoS One. 8:e641382013.
View Article : Google Scholar : PubMed/NCBI
|
